PDCD1 and non-small cell lung carcinoma: Although two reports have reviewed the safety of PD-1 and PD-L1 inhibitors in the treatment of malignancies, the results were not entirely consistent [9, 10], and to our knowledge, no systematic reviews or meta-analyses of irAEs associated with PD-1/PD-L1 inhibitors for NSCLC using the Common Terminology Criteria as the outcome metric have been published in the literature.